TOKYO, June 21, 2011 ─ Astellas Pharma Inc. (“Astellas”; Tokyo:4503) and Abbott Japan Co., Ltd. (“Abbott”) today announced that Astellas will transfer the rights to distribute the selective serotonin reuptake inhibitor (SSRI) Luvox® Tablets (generic name: fluvoxamine maleate) to Abbott effective on April 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.
Astellas will continue the distribution and promotion until March 31, 2012.
The impact from this agreement on Astellas’ financial forecast on the current fiscal year (from April 1, 2011 to March 31, 2012) will be immaterial.
###
